The Prevalence of Cancer in Patients with Multiple Sclerosis (MS) who were Under Treatment with Natalizumab (Tysabri): A Systematic Review and Meta‑Analysis

Amirreza Nasirzadeh, Reza Jahanshahi, Mahsa Ghajarzadeh, Aida Mohammadi, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi

Abstract


Background: To determine the pooled prevalence of cancer in subjects with multiple sclerosis (MS) who received Natalizumab. Methods: Two researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, google scholar, and gray literature including references of the included studies. The search strategy which was used in PubMed was (“Disseminated Sclerosis” OR “multiple sclerosis” OR “MS” OR “Acute Fulminating”) AND (“Cancer” OR “Neoplasia*” OR “Neoplasm*” OR “Tumor*” OR “Malignancy” OR “Benign Neoplasm” OR “Malignant neoplasm”) AND (“Tysabri” OR “Antegren” OR “natalizumab” OR “Modifying Therapy”). Results: We found 1,993 articles by literature search, and 1,573 studies remained after removing duplicate studies. For metaanalysis, we used the extracted data of eight studies. The pooled prevalence of cancer in patients who received Natalizumab was 2% (95%CI: 1–3%; I 2: 99.4%, P < 0.001). The pooled prevalence of basal cell carcinoma in patients with cancer was 12% (95%CI: 5–20%; I2 :50.3%, P = 0.13). Conclusions: The main finding of this systematic review and metaanalysis is that the pooled prevalence of cancer in subjects who suffer from MS and received natalizumab was 2%.

International Journal of Preventive Medicine 14(1):114, September 2023. | DOI: 10.4103/ijpvm.ijpvm_77_22

 

Corresponding Author: Dr. Abdorreza Naser Moghadasi

E‑mail: abdorrezamoghadasi@gmail.com

You can also search for this author in: PubMed  Google Scholar


Keywords


Multiple sclerosis; neoplasm; prevalence

Full Text:

PDF

References


Ghajarzadeh M, Jalilian R, Sahraian MA, Moghadasi AN,

Azimi A, Mohammadifar M, et al. Pain in patients with multiple

sclerosis. Maedica 2018;13:125.

Ghajarzadeh M, Azizi S, Moghadasi AN, Sahraian MA, Azimi A,

Mohammadifar M, et al. Validity and reliability of the Persian

version of the PERception de la Scle’rose En Plaques et de ses

Pousse’es questionnaire evaluating multiple sclerosis‑related

quality of life. Int J Prev Med 2016;7:25.

Piehl F. A changing treatment landscape for multiple sclerosis:

Challenges and opportunities. J Intern Med 2014;275:364‑81.

Alping P, Askling J, Burman J, Fink K, Fogdell‑Hahn A,

Gunnarsson M, et al. Cancer risk for fingolimod, natalizumab,

and rituximab in multiple sclerosis patients. Ann Neurol

;87:688‑99.

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL,

Radue EW, et al. Natalizumab plus interferon beta‑1a for

relapsing multiple sclerosis. N Engl J Med 2006;354:911‑23.

Azimi A, Hanaei S, Sahraian MA, Mohammadifar M,

Ramagopalan SV, Ghajarzadeh M. Incidence of seroconversion

and sero‑reversion in patients with multiple sclerosis (MS) who

had been treated with natalizumab: A systematic review and

meta‑analysis. J Clin Neurosci 2020;71:129‑34.

Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV,

Ghajarzadeh M, Ghajarzadeh M. Prevalence of Anti‑JC virus

antibody seropositivity in patients with multiple sclerosis:

A systematic review and meta‑analysis. Intervirology

;62:169‑73.

Brønnum‑Hansen H, Koch‑Henriksen N, Stenager E. Trends

in survival and cause of death in Danish patients with multiple

sclerosis. Brain 2004;127:844‑50.

Grytten Torkildsen N, Lie S, Aarseth J, Nyland H, Myhr K. Survival

and cause of death in multiple sclerosis: Results from a 50‑year

follow‑up in Western Norway. Mult Scler J 2008;14:1191‑8.

Hirst C, Swingler R, Compston D, Ben‑Shlomo Y, Robertson NP.

Survival and cause of death in multiple sclerosis: A prospective

population‑based study. J Neurol Neurosurg Psychiatry

;79:1016‑21.

Smestad C, Sandvik L, Celius E. Excess mortality and cause of

death in a cohort of Norwegian multiple sclerosis patients. Mult

Scler J 2009;15:1263‑70.

Ghajarzadeh M, Mohammadi A, Sahraian MA. Risk of cancer in

multiple sclerosis (MS): A systematic review and meta‑analysis.

Autoimmun Rev 2020;19:102650.

Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al.

Assessing risk of bias in prevalence studies: Modification of

an existing tool and evidence of interrater agreement. J Clin

Epidemiol 2012;65:934‑9.

Carbone ML, Lacal PM, Messinese S, De Giglio L, Pozzilli C,

Persechino S, et al. Multiple sclerosis treatment and melanoma

development. Int J Mol Sci 2020;21:2950.

Singer BA. The role of natalizumab in the treatment of

multiple sclerosis: Benefits and risks. Ther Adv Neurol Disord

;10:327‑36.

Lebrun C, Rocher F. Cancer risk in patients with multiple

sclerosis: Potential impact of disease‑modifying drugs. CNS

Drugs 2018;32:939‑49.

Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer

prevalence for 27 sites in the adult population in 2008. Int J

Cancer 2013;132:1133‑45.

Foley J, Carrillo‑Infante C, Smith J, Evans K, Ho P‑R, Lee L,

et al. The 5‑year Tysabri global observational program in

safety (TYGRIS) study confirms the long‑term safety profile of

natalizumab treatment in multiple sclerosis. Mult Scler Relat

Disord 2020;39:101863.

Stamatellos VP, Siafis S, Papazisis G. Disease‑modifying

agents for multiple sclerosis and the risk for reporting cancer:

A disproportionality analysis using US Food and Drug

Administration Adverse Event Reporting System (FAERS)

database. Br J Clin Pharmacol 2021;87:4769‑79.

Polman CH, O’Connor PW, Havrdova E, Hutchinson M,

Kappos L, Miller DH, et al. A randomized, placebo‑controlled

trial of natalizumab for relapsing multiple sclerosis. N Engl J

Med 2006;354:899‑910.

Babaesfahani A, Khanna NR, Kuns B. Natalizumab. StatPearls.

Treasure Island (FL): StatPearls Publishing; 2021.

Castela E, Lebrun‑Frenay C, Laffon M, Rocher F, Cohen M,

Leccia NC, et al. Evolution of nevi during treatment with

natalizumab: A prospective follow‑up of patients treated with

natalizumab for multiple sclerosis. Arch Dermatol 2011;147:72‑6.